LAGUNA HILLS, CA and SHANGHAI- April 23, 2022, The Avenir® Plus Coil System, an important addition to the Avenir Coil System, independently developed by Wallaby Medical Holding, Inc. (hereinafter referred to as Wallaby Medical) was recently approved by the National Medical Products Administration (NMPA) to be marketed in China.
The new Avenir Plus Coil System includes 65 new sizes and offers a redesigned primary wire and coil size, adding to the existing Avenir Coil System.
The objective in the endovascular treatment of aneurysms with embolic coils is to safely and efficiently achieve a dense packing of the aneurysm, effectively isolating it from blood flow, and risk of future rupture or re-rupture. Smaller softer coils, such as those included in the new Avenir Plus Coil System, aim to assist physicians in achieving such dense packing.
Since initial commercialization in 2021, nearly 100 comprehensive stroke centers in China have completed clinical procedures with the Avenir Coil System, and have found the performance to be exceptional.
"Endovascular coil embolization is one of the mainstream treatment methods for intracranial aneurysms. The approval of the Plus series indicates that the Avenir Coil System has been further improved and will benefit more patients in the future," said Mr. Michael Alper, CEO of Wallaby Medical.
©2022 Wallaby Medical. All Rights Reserved Official Wechat
©2022 Wallaby Medical. All Rights Reserved